The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
GI Malignancies Debate 2022 | Checkpoint inhibition in hepatocellular carcinoma
Ghassan Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of immune checkpoint inhibitors (ICIs) in treating hepatocellular carcinoma. Current double therapies incorporating ICIs including durvalumab and tremelimumab as well as atezolizumab and bevacizumab have been assessed in clinical trials such as the Phase III IMbrave150 trial (NCT03434379) of the latter combination against sorafenib. Prof. Abou-Alfa additionally highlights data from a real world study which shows patients with hepatitis B are especially more likely to benefit from checkpoint inhibition. This interview took place virtually at the 2022 Great Debates & Updates in Gastrointestinal Malignancies Congress.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
